Send to

Choose Destination
Curr Pharm Des. 2018;24(11):1157-1173. doi: 10.2174/1381612823666170913163904.

Development of Peptide Vaccines in Dengue.

Author information

Research Centre for Biomedical Sciences, Sunway University, Bandar Sunway, Subang Jaya, Selangor, Malaysia.
Department of Biological Science, School of Science and Technology, Sunway University, Bandar Sunway, Subang Jaya, Selangor, Malaysia.
Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia.


Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.


Dengue; HLA; cell mediated immunity; multi-epitope; peptide vaccine; synthetic peptides.

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd. Icon for PubMed Central
Loading ...
Support Center